Drug Shortage Report for TEVA-IRBESARTAN

Last updated on 2021-05-06 History
Report ID 92171
Drug Identification Number 02316390
Brand name TEVA-IRBESARTAN
Common or Proper name IRBESARTAN
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) IRBESARTAN
Strength(s) 75MG
Dosage form(s) TABLET
Route of administration ORAL
Packaging size 100
ATC code C09CA
ATC description ANGIOTENSIN II ANTAGONISTS, PLAIN
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2019-08-22
Estimated end date 2021-07-31
Actual end date 2021-05-05
Shortage status Resolved
Updated date 2021-05-06
Company comments Will continue to allocate until regular supply can be restored (TBD) Allocating 100% of Teva market share from July to August.
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v34 2021-05-06 French Compare
v33 2021-05-06 English Compare
v32 2021-02-11 French Compare
v31 2021-02-11 English Compare
v30 2020-09-22 French Compare
v29 2020-09-22 English Compare
v28 2020-07-14 French Compare
v27 2020-07-14 English Compare
v26 2020-06-18 French Compare
v25 2020-06-18 English Compare
v24 2020-05-14 French Compare
v23 2020-05-14 English Compare
v22 2020-05-08 English Compare
v21 2020-05-01 French Compare
v20 2020-05-01 English Compare
v19 2020-04-23 French Compare
v18 2020-04-23 English Compare
v17 2020-04-09 French Compare
v16 2020-04-09 English Compare
v15 2020-02-07 French Compare

Showing 1 to 20 of 34